These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

187 related items for PubMed ID: 6383127

  • 21. [Bencyclane in stage II arterial occlusive disease. Results of a controlled study].
    Trübestein G, Trübestein R, Ludwig M.
    Fortschr Med; 1989 Dec 20; 107(36):781-4. PubMed ID: 2695437
    [Abstract] [Full Text] [Related]

  • 22.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 23. [Effect of the vasoactive drug buflomedil in arterial occlusive disease].
    Racenberg J, Intaglietta M, Messmer K.
    Fortschr Med; 1982 Nov 04; 100(41):1926-30. PubMed ID: 7152426
    [Abstract] [Full Text] [Related]

  • 24. Experience with buflomedil in peripheral arterial occlusive disease.
    Balas P, Pagratis N.
    Angiology; 1981 Oct 04; 32(10):679-85. PubMed ID: 7325404
    [No Abstract] [Full Text] [Related]

  • 25. Restoring vascular nitric oxide formation by L-arginine improves the symptoms of intermittent claudication in patients with peripheral arterial occlusive disease.
    Böger RH, Bode-Böger SM, Thiele W, Creutzig A, Alexander K, Frölich JC.
    J Am Coll Cardiol; 1998 Nov 04; 32(5):1336-44. PubMed ID: 9809945
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. [Buflomedil chlorhydrate in peripheral vasculopathies].
    Dall'Antonia F, Perbellini A, Adami CA, Dal Cortivo G, Bucci S.
    Clin Ter; 1986 Dec 15; 119(5):379-85. PubMed ID: 2951055
    [No Abstract] [Full Text] [Related]

  • 28. Effect of buflomedil on behaviour, memory, and intellectual capacity in patients with dementia. A placebo-controlled study.
    Levinson B, Wright P, Barklem S.
    S Afr Med J; 1985 Aug 31; 68(5):302-7. PubMed ID: 3898413
    [Abstract] [Full Text] [Related]

  • 29. Comparative evaluation of the effectiveness of buflomedil and pentoxifylline in patients with arterial occlusive disease.
    Trübestein G, Trübestein R, Duong QD.
    Angiology; 1981 Oct 31; 32(10):705-10. PubMed ID: 7034591
    [Abstract] [Full Text] [Related]

  • 30. Intravenous treatment of chronic peripheral occlusive arterial disease: a double-blind, placebo-controlled, randomized, multicenter trial of pentoxifylline.
    Rudofsky G, Haussler KF, Künkel HP, Schneider-May H, Spengel F, Symann O, Werner HJ.
    Angiology; 1989 Jul 31; 40(7):639-49. PubMed ID: 2662830
    [Abstract] [Full Text] [Related]

  • 31. [Vascular and hemorheologic effects of buflomedil chlorhydrate in chronic obliterative arteriopathies of the legs].
    Coglitore S, Manganaro A, Barbera MC, Cento D, Buda D, Arrigo F, Consolo F.
    Minerva Cardioangiol; 1986 Nov 31; 34(11):745-9. PubMed ID: 2949163
    [No Abstract] [Full Text] [Related]

  • 32. [Clinical experience and instrumental evaluation of buflomedil hydrochloride in the therapy of chronic obliterative arteriopathies of the legs].
    Lucisano V, Margheriti R, Matone P, Morrieri C, Rugolo A, Corsi V.
    Clin Ter; 1986 Jun 30; 117(6):499-509. PubMed ID: 3527536
    [No Abstract] [Full Text] [Related]

  • 33. Multicentre clinical placebo-controlled study with buflomedil in the treatment of mild dementia of vascular origin.
    Cucinotta D, Aveni Casucci MA, Pedrazzi F, Ponari O, Capodaglio M, Valdina P, Toxiri I, Bartorelli L, Granata Q, Franzini C.
    J Int Med Res; 1992 Apr 30; 20(2):136-49. PubMed ID: 1521670
    [Abstract] [Full Text] [Related]

  • 34. Effects of buflomedil hydrochloride in occlusive arterial disease of the lower limbs stage IV.
    Briguglio F, Briguglio E, Di Marco V, Swat M, Materia G, Intilisano A.
    J Int Med Res; 1986 Apr 30; 14(3):115-23. PubMed ID: 3721052
    [Abstract] [Full Text] [Related]

  • 35. Walk training and drug treatment in patients with peripheral arterial occlusive disease stage II. A review.
    Spitzer S, Bach R, Schieffer H.
    Int Angiol; 1992 Apr 30; 11(3):204-10. PubMed ID: 1460355
    [Abstract] [Full Text] [Related]

  • 36. [Comparative study of various schedules of buflomedil treatment in peripheral arterial insufficiency of the lower limbs. Evaluation of its therapeutic efficacy].
    Paoletti V, Mammarella A, Alessandrini A, Barlattani M.
    Clin Ter; 1984 Jul 15; 110(1):29-36. PubMed ID: 6237843
    [No Abstract] [Full Text] [Related]

  • 37. [Naftidrofuryl in arterial occlusive disease. Controlled multicenter double-blind study with oral administration].
    Maass U, Amberger HG, Böhme H, Diehm C, Dimroth H, Heidrich H, Heinrich F, Hirche H, Mörl H, Müller-Bühl U.
    Dtsch Med Wochenschr; 1984 May 11; 109(19):745-50. PubMed ID: 6373217
    [Abstract] [Full Text] [Related]

  • 38. Encephalotropic and psychotropic effects of intravenous buflomedil in the elderly: double-blind, placebo-controlled pharmaco-EEG and psychometric studies.
    Saletu B, Grünberger J, Linzmayer L, Stöhr H.
    Int J Clin Pharmacol Res; 1984 May 11; 4(2):95-107. PubMed ID: 6469443
    [Abstract] [Full Text] [Related]

  • 39. [Doppler flowmeter evaluation of the effects of the administration of buflomedil (irrodan) on peripheral circulation in patients with obstructive chronic arteriopathy].
    Abate S, Ferulano GP, Vanni L, Dilillo S, Picilli M, D'Alessio E.
    Minerva Cardioangiol; 1985 Nov 11; 33(11):749-56. PubMed ID: 2935748
    [No Abstract] [Full Text] [Related]

  • 40. [New data on vasoactive drug. Patients with peripheral arterial occlusive disease walk twice as long].
    MMW Fortschr Med; 2002 May 23; 144(21):54. PubMed ID: 12134429
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 10.